\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Stock Quote

NASDAQCRDF
$9.15
NASDAQCRDF
Open
$9.83
Change
-$0.57 (-5.86%)
Day's Range
$9.12 - $9.90
52-Week Range
$0.71 - $25.50
Volume
705.5K
Market Cap
$339.0M